Related Experiment Video

Updated: Feb 27, 2026

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
06:32

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats

Published on: June 28, 2019

8.5K

Fractional flow reserve (FFR)-based therapy in patients presenting with acute coronary syndrome: Current data and

Grzegorz Zuk1, Dariusz Ciecwierz, Natalia Cwalina

  • 1First Department of Cardiology, Medical University of Gdansk, Debinki 7, 80-952, Gdansk, Poland. grzegorz.zuk13@gmail.com cedario@o2.pl.

Cardiology Journal
|June 28, 2017
PubMed

Insights

Fractional flow reserve (FFR) in acute coronary syndrome (ACS) is less reliable due to microvascular dysfunction, making its clinical role controversial. More research is needed to understand FFR

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Cardiovascular Physiology

Background:

  • Fractional flow reserve (FFR) is an established diagnostic tool for coronary artery stenosis in stable coronary artery disease (CAD).
  • Microvascular dysfunction in acute coronary syndrome (ACS) can affect FFR reliability.
  • The clinical utility of FFR in ACS remains debated due to conflicting study results.

Purpose of the Study:

  • To review the current knowledge on the application of FFR in the setting of ACS.
  • To highlight the controversies and limitations of FFR use in acute scenarios.

Main Methods:

  • Review of existing literature and clinical trials on FFR in ACS.
  • Analysis of discrepant study findings regarding FFR efficacy in ACS.

Main Results:

  • Limited randomized clinical trials exist for FFR-guided percutaneous coronary intervention in ACS.
  • Published studies show inconsistent outcomes, indicating a need for further investigation.
  • FFR's role in acute settings is substantially understudied.

Conclusions:

  • The reliability of FFR in ACS is questionable due to underlying pathophysiology.
  • Further research, including robust clinical trials, is essential to define FFR's role in managing ACS patients.

Keywords:
acute coronary syndromecoronary revascularizationfractional flow reservehyperemiamicrocirculation

More Related Videos

Author Spotlight: Improved Localization and Monitoring of Coronary Flow Reserve Using Modified PLAX View in Mice05:07

Author Spotlight: Improved Localization and Monitoring of Coronary Flow Reserve Using Modified PLAX View in Mice

Published on: August 25, 2023

2.1K
Ultrasound Based Assessment of Coronary Artery Flow and Coronary Flow Reserve Using the Pressure Overload Model in Mice06:39

Ultrasound Based Assessment of Coronary Artery Flow and Coronary Flow Reserve Using the Pressure Overload Model in Mice

Published on: April 13, 2015

15.8K

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
347
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
343
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
466
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
414
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
419
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
366